The stock price of Sutro Biopharma Inc (NASDAQ: STRO) has surged by 5.90 when compared to previous closing price of 0.60, but the company has seen a -17.64% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-15 that – The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater – – The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater –
Is It Worth Investing in Sutro Biopharma Inc (NASDAQ: STRO) Right Now?
The 36-month beta value for STRO is also noteworthy at 1.89. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 6 rating it as “hold,” and 0 rating it as “sell.”
The public float for STRO is 75.61M, and at present, short sellers hold a 6.13% of that float. The average trading volume of STRO on April 03, 2025 was 1.35M shares.
STRO’s Market Performance
The stock of Sutro Biopharma Inc (STRO) has seen a -17.64% decrease in the past week, with a -55.61% drop in the past month, and a -65.92% fall in the past quarter. The volatility ratio for the week is 11.69%, and the volatility levels for the past 30 days are at 12.19% for STRO. The simple moving average for the past 20 days is -33.12% for STRO’s stock, with a -78.00% simple moving average for the past 200 days.
Analysts’ Opinion of STRO
Wedbush, on the other hand, stated in their research note that they expect to see STRO reach a price target of $2, previously predicting the price at $8. The rating they have provided for STRO stocks is “Neutral” according to the report published on March 14th, 2025.
STRO Trading at -56.69% from the 50-Day Moving Average
After a stumble in the market that brought STRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.28% of loss for the given period.
Volatility was left at 12.19%, however, over the last 30 days, the volatility rate increased by 11.69%, as shares sank -53.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -68.32% lower at present.
During the last 5 trading sessions, STRO fell by -17.64%, which changed the moving average for the period of 200-days by -83.63% in comparison to the 20-day moving average, which settled at $0.9426. In addition, Sutro Biopharma Inc saw -65.74% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for STRO
Current profitability levels for the company are sitting at:
- -3.84 for the present operating margin
- -0.03 for the gross margin
The net margin for Sutro Biopharma Inc stands at -3.67. The total capital return value is set at -0.93. Equity return is now at value -234.19, with -53.02 for asset returns.
Based on Sutro Biopharma Inc (STRO), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -8.27. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is -6.8.
Currently, EBITDA for the company is -186.81 million with net debt to EBITDA at 0.89. When we switch over and look at the enterprise to sales, we see a ratio of -1.84. The receivables turnover for the company is 7.2for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.60.
Conclusion
In summary, Sutro Biopharma Inc (STRO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
